This site is archived and is no longer updated. It will be taken offline in mid-July. All the latest AWMSG recommendations, guidance and information is available on our new website at: https://awmsg.nhs.wales/.
awmsg logo



brentuximab vedotin (Adcetris®)


Reference No. 2074

Publication date:
12/06/2019


Appraisal information

brentuximab vedotin (Adcetris®) 50 mg powder for concentrate for solution for infusion


Company: Takeda UK Ltd
BNF category: Malignant disease and immunosupression
NMG meeting date: Not scheduled
AWMSG meeting date: Not scheduled
   
   
Submission Type: Nonsubmission
Status: Not endorsed
Advice No: Not available
Ratification by Welsh Government: 11/06/2019

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

AWMSG advice

In the absence of a submission from the holder of the marketing authorisation, brentuximab vedotin (Adcetris®) cannot be endorsed for use within NHS Wales for adult patients with previously untreated CD30+ Stage IV Hodgkin lymphoma (HL) in combination with doxorubicin, vinblastine and dacarbazine (AVD)
Statement of Advice (SOA)
Download